


**Product Name** : 4A7C-301  
**Cat. No.** : PC-21004  
**CAS No.** :  
**Molecular Formula** : C<sub>27</sub>H<sub>38</sub>ClN<sub>9</sub>  
**Molecular Weight** : 524.11  
**Target** : NURR1 (NR4A2)  
**Solubility** : 10 mM in DMSO



## Biological Activity

4A7C-301 is a potent, selective, brain-penetrant agonist of nuclear receptor **Nurr1** with EC<sub>50</sub> of 6.53 μM, binds to Nurr1 ligand binding domain (LBD) with IC<sub>50</sub> of 50 nM.

4A7C-301 shows higher potency than chloroquine (CQ), exhibits approximately 50 times higher potency than CQ in N27-A cells (EC<sub>50</sub>= ~0.2 and ~10 μM, respectively).

4A7C-301 selectively activates the transcriptional activity of Nurr1, but not Nur77, over Nor1.

4A7C-301 induces Nurr1's transcriptional activity with the greatest potency (13-14 fold) among NR4A members in SK-N-BE(2)C cells.

4A7C-301 restores Nurr1 protein expression levels that are diminished by exposure to environmental and genetic risk factors of PD in vitro.

4A7C-301 suppresses neuroinflammation in ventral mesencephalic (VM) neuron-glia co-cultures.

4A7C-301 restores autophagy against MPP<sup>+</sup> in vitro.

4A7C-301 (5 mg/kg/day) 4A7C-301 protects midbrain dopamine neurons in the MPTP-induced male mouse model of PD and improves both motor and non-motor olfactory deficits without dyskinesia-like behaviors.

4A7C-301 also significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α-synuclein-overexpressing male mouse models.

## References

Woori Kim, et al. *Nat Commun.* 2023 Jul 18;14(1):4283.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com